Citius Pharmaceuticals, Inc. (CTXR) · Oct 26, 2026 · Earnings
120% unit growth — 792 wholesaler units vs 360 in fiscal Q3
Citius Pharmaceuticals’ earnings update shows LYMPHIR wholesaler shipments more than doubling, while institutional demand growth remains modest and unaudited.
Citius is in the early commercial ramp of LYMPHIR, launched in December 2025 for relapsed or refractory cutaneous T-cell lymphoma; the business is shifting from regulatory execution to proving repeatable demand across U.S. treatment centers. The expanded commercial team reached nationwide coverage in August, making this the first quarter that tests whether the larger sales effort is translating into shipments.
Wholesaler shipments accelerated sharply. Preliminary LYMPHIR purchases by U.S. wholesalers rose to 792 units from 360 in fiscal Q3, a 120% increase, which should translate into materially higher recognized revenue because Citius records revenue when wholesaler orders are fulfilled. 〔0〕
The underlying treatment-center demand signal is much less dramatic. Institutional vial orders reached 950 versus 926 in the prior quarter, while the number of ordering institutions rose to 54 from 44. That suggests the shipment jump may reflect wholesaler restocking and channel build-out as much as a comparable surge in patient treatment volume; the company itself cautions that quarterly shipments can fluctuate with wholesaler purchasing patterns and inventory levels.
This advances the launch, but does not yet prove a fully established revenue engine. The company is more than halfway toward its goal of formulary placement at 100 priority institutions by year-end, and management expects continued sales growth in fiscal 2027. 〔1〕 The direction was already expected after prior reports of expanding institutional access and a larger commercial organization; the new information is the size of the wholesaler shipment increase, tempered by only modest growth in institutional vial orders.
The evidence is still preliminary rather than a clean earnings beat. No revenue, gross-to-net adjustment, profitability, or cash-flow figures were disclosed, and the unit data remains unaudited. Complete fiscal fourth-quarter and fiscal-year 2026 results are expected in December 2026. 〔2〕
Bottom line: The filing confirms that LYMPHIR’s commercial rollout is gaining reach, but the strongest number is wholesaler movement rather than end-demand. It is meaningful progress for the launch, not yet proof that institutional treatment volume is scaling at the same pace.
FY2026 results and 10-K, December 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!